Choose Kacsmaryk, an appointee of Mr. Trump, is a longtime opponent of abortion and joined the bench after working at First Liberty Institute, a conservative authorized group that focuses on points of non secular liberty.
The coalition that introduced the go well with, the Alliance for Hippocratic Drugs, argued that the F.D.A. had improperly accepted the capsule in 2000 and that mifepristone is unsafe. The company has strongly disputed these claims, pointing to research that present that severe issues are uncommon and that lower than 1 % of sufferers want hospitalization.
This month, Choose Kacsmaryk, in a short lived ruling, declared invalid the F.D.A.’s approval of the drug and gave each events every week to hunt emergency aid earlier than the choice took impact.
Lower than an hour later, a federal choose in Washington State, Thomas O. Rice, an appointee of President Barack Obama, issued a contradictory ruling in a separate lawsuit over mifepristone. Choose Rice blocked the F.D.A. from limiting the provision of the capsule in 17 states and the District of Columbia, which had been events in that go well with.
The competing rulings meant that the matter was nearly actually headed to the Supreme Court docket.
The F.D.A. instantly appealed Choose Kacsmaryk’s choice, and a divided three-judge panel of the Fifth Circuit, in New Orleans, upheld the company’s approval of the drug, guaranteeing that mifepristone would stay in the marketplace.
However the panel imposed a number of boundaries to entry, siding partly with Choose Kacsmaryk, whereas the lawsuit moved by the courts. It blocked a sequence of steps the F.D.A. had taken since 2016 to extend the provision and distribution of the drug, comparable to permitting it to be despatched by mail and to be prescribed by medical suppliers who should not medical doctors.
Adam Liptak and Christina Jewett contributed reporting.